Edesa Biotech reported financial results for the fiscal year ended September 30, 2025.
The company initiated manufacturing activities for a Phase 2 study of EB06 in patients with vitiligo.
Edesa reported positive results from a Phase 3 study of paridiprubart.
Phase 2 Study Initiated
Manufacturing activities commenced for EB06 Phase 2 study in vitiligo patients.
Phase 3 Success
Positive outcomes from Phase 3 study of paridiprubart with significant endpoints met.
Financial Highlights
Total operating expenses increased to $7.9 million, with a net loss of $7.2 million reported.
- Edesa is progressing well with its dermatology and respiratory programs, positioning itself for transformative therapy delivery.
- Strategic partnerships and government collaborations are being sought to support program advancements and financial stability.
Edesa Biotech's strong financial performance and progress in clinical studies demonstrate a promising trajectory for future growth and development. Strategic partnerships and ongoing program advancements highlight a commitment to addressing unmet medical needs.